<DOC>
	<DOCNO>NCT00005992</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's peripheral stem cell may make body build immune response kill tumor cell . PURPOSE : Phase I trial study effectiveness vaccine therapy treat patient metastatic prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Metastatic Prostate Cancer That Has Not Responded Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : I. Assess safety recombinant prostate-specific membrane antigen ( rPSMA ) -pulsed autologous dendritic cell ( CaPVax ) patient metastatic hormone-refractory prostate cancer . II . Determine potential clinical response patient treat regimen . III . Determine effect treatment regimen pain , physical function , quality life patient . OUTLINE : This dose-escalation , multicenter study . Patients undergo delayed hypersensitivity skin test 3 common recall antigen . Autologous dendritic cell ( DC ) pulse recombinant prostate-specific membrane antigen ( rPSMA ) . Patients receive rPSMA-pulsed autologous DC ( CaPVax ) intradermally . Treatment repeat every 4 week total 4 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos CaPVax maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Quality life questionnaire complete five time course study . Patients follow 3 month . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic hormonerefractory prostate cancer Castrate serum testosterone le 30 ng/dL antiandrogen withdrawal Progressing disease 50 % increase PSA level nadir PSA level confirm twice measure least 2 week apart OR New bone pain new lesion bone scan OR Progression soft tissue disease CT MRI Limited bone disease No 3 metastatic site bone scan minimal symptom No brain metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 01 Life expectancy : At least 1 year Hematopoietic : Hemoglobin great 12.5 g/dL Absolute lymphocyte count great 500/mm3 Absolute neutrophil count great 1,000/mm3 Platelet count great 150,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL SGOT/SGPT le 2 time upper limit normal Hepatitis C negative Hepatitis B surface antigen hepatitis B core antigen negative No uncontrolled liver disease Renal : Creatinine le 2.5 mg/dL Creatinine clearance great 50 mL/min No uncontrolled renal disease Cardiovascular : No uncontrolled heart disease Immunologic : No history severe asthma , anaphylaxis , serious adverse reaction vaccine antigen include skin test No immunodeficiency autoimmune disease rheumatoid arthritis , systemic lupus erythematosus , scleroderma , polymyositis dermatomyositis , juvenileonset insulindependent diabetes , vasculitis Negative PPD skin test No prior BCG vaccination tuberculosis exposure HIV negative Other : No impend untreated spinal cord compression urinary outlet obstruction No serious concurrent illness No prior malignancy past 2 year except curatively treat basal cell squamous cell carcinoma skin PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy metastatic disease Endocrine therapy : See Disease Characteristics Hormonal therapy ( except antiandrogens like LHRH ) must continue Radiotherapy : No prior radiotherapy metastatic disease include strontium chloride Sr 89 Surgery : No prior splenectomy Other : No prior ketoconazole At least 4 week since prior immunosuppressive ( e.g. , prednisone hydrocortisone ) No prior investigational agent No concurrent medication may affect immune function except nonprescription strength dose nonsteroidal antiinflammatory drug , acetaminophen , aspirin ; low dos antihistamine ; normal dos vitamin ; H2 blockers No 2 short course ( 10 day per course ) antibiotic treatment minor infection 45 day span</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2002</verification_date>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>